Clinics in Dermatology
Volume 24, Issue 4 , Pages 289-298 , July 2006

Dermatology of androgen-related disorders

  • Paulina A. Essah, MD, MS

      Affiliations

    • Department of Internal Medicine, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 804 828 9696; fax: +1 804 828 8389.
    • ,
  • Edmond P. Wickham III, MD

      Affiliations

    • Department of Internal Medicine, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298, USA
    • ,
  • Julia R. Nunley, MD

      Affiliations

    • Department of Dermatology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298, USA
    • ,
  • John E. Nestler, MD

      Affiliations

    • Department of Internal Medicine, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298, USA
    • Department of Obstetrics and Gynecology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298, USA

References 

  1. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med. 2000;132:989–993
  2. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078–3082
  3. Judd HL, Scully RE, Herbst AL, et al. Familial hyperthecosis: comparison of endocrinologic and histologic findings with polycystic ovarian disease. Am J Obstet Gynecol. 1973;117:976–982
  4. Bulun SE, Adashi EY. The physiology and pathology of the female reproductive system. In:  Larsen PR,  Kronenberg HM,  Melmed S,  Polonsky KS editor. Williams textbook of endocrinology. 10th ed.. Philadelphia: Saunders; 2002;p. 587–664
  5. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89:453–462
  6. Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:4116–4123
  7. Falsetti L, Gambera A, Andrico S, Sartori E. Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine-metabolic and ultrasonographic differences. Gynecol Endocrinol. 2002;16:275–284
  8. New MI. An update of congenital adrenal hyperplasia. Ann N Y Acad Sci. 2004;1038:14–43
  9. Rosenfield RL. Puberty in the female and its disorders. In:  Sperling MA editors. Pediatric endocrinology. 2nd ed.. Philadelphia: Saunders; 2002;p. 455–518
  10. Witchel SF, Finegold DN. Endocrinology. In:  Zitelli BJ,  Davis HW editor. Atlas of pediatric physical diagnosis. 4th ed.. Philadelphia: Mosby; 2002;p. 315–336
  11. Kaplowitz PB, Oberfield SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and therapeutics and executive committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics. 1999;104:936–941
  12. Voutilainen R, Perheentupa J, Apter D. Benign premature adrenarche: clinical features and serum steroid levels. Acta Paediatr Scand. 1983;72:707–711
  13. Miller D, Emans SJ, Kohane I. Follow-up study of adolescent girls with a history of premature pubarche. J Adolesc Health. 1996;18:301–305
  14. Ibanez L, Potau N, Virdis R, et al. Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1993;76:1599–1603
  15. Franks S, Kiddy D, Sharp P, et al. Obesity and polycystic ovary syndrome. Ann N Y Acad Sci. 1991;626:201–206
  16. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18:774–800
  17. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141–146
  18. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:1929–1935
  19. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism. 2003;52:908–915
  20. Franks S. Adult polycystic ovary syndrome begins in childhood. Best Pract Res Clin Endocrinol Metab. 2002;16:263–272
  21. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223–1236
  22. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev. 2000;21:347–362
  23. Rittmaster RS. Hirsutism. Lancet. 1997;349:191–195
  24. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol. 2003;101:995–1007
  25. Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:737–754
  26. Speroff L, Glass RH, Kase NG. Hirsutism. In:  Speroff L,  Glass RH,  Kase NG editor. Clinical gynecologic endocrinology and infertility. 6th ed.. Baltimore: Williams and Wilkins; 1999;p. 523–556
  27. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–1447
  28. Hatch R, Rosefield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981;140:815–830
  29. Homburg R, Lambalk CB. Polycystic ovary syndrome in adolescence—a therapeutic conundrum. Hum Reprod. 2004;19:1039–1042
  30. Bunker CB, Newton JA, Kilborn J, et al. Most women with acne have polycystic ovaries. Br J Dermatol. 1989;121:675–680
  31. Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004;22:419–428
  32. Lucky AW, McGuire J, Rosenfield RL, Lucky PA, Rich BH. Plasma androgens in women with acne vulgaris. J Invest Dermatol. 1983;81:70–74
  33. Schiavone FE, Rietschel RL, Sgoutas D, Harris R. Elevated free testosterone levels in women with acne. Arch Dermatol. 1983;119:799–802
  34. Scholl GM, Wu CH, Leyden J. Androgen excess in women with acne. Obstet Gynecol. 1984;64:683–688
  35. Timpatanapong P, Rojanasakul A. Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne. J Dermatol. 1997;24:223–229
  36. Henze C, Hinney B, Wuttke W. Incidence of increased androgen levels in patients suffering from acne. Dermatology (Switzerland). 1998;196:53–54
  37. Cibula D, Hill M, Vohradnikova O, et al. The role of androgens in determining acne severity in adult women. Br J Dermatol. 2000;143:399–404
  38. Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol. 2002;119:992–1007
  39. Panidis D, Skiadopoulos S, Rousso D, Ioannides D, Panidou E. Association of acanthosis nigricans with insulin resistance in patients with polycystic ovary syndrome. Br J Dermatol. 1995;132:936–941
  40. Torley D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. Br J Dermatol. 2002;147:1096–1101
  41. Cruz PD, Hud JA. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol. 1992;98(Suppl):82S–85S
  42. Flier JS. Metabolic importance of acanthosis nigricans. Arch Dermatol. 1985;121:193–194
  43. Fleming MG, Simon SI. Cutaneous insulin reaction resembling acanthosis nigricans. Arch Dermatol. 1986;122:1054–1056
  44. Erickson L, Lipschutz DE, Wrigley W, Kearse WO. A peculiar cutaneous reaction to repeated injections of insulin. JAMA. 1969;209:934–935
  45. Flier JS, Usher P, Moses AC. Monoclonal antibody to the type I insulin–like growth factor (IGF-I) receptor blocks IGF-I receptor–mediated DNA synthesis: clarification of the mitogenic mechanisms of IGF-I and insulin in human skin fibroblasts. Proc Natl Acad Sci U S A. 1986;83:664–668
  46. Verrando P, Ortonne JP. Insulin binding properties of normal and transformed human epidermal cultured keratinocytes. J Invest Dermatol. 1985;85:328–332
  47. Cela E, Robertson C, Rush K, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol. 2003;149:439–442
  48. Futterweit W, Dunaif A, Yeh HC, Kingsley P. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol. 1988;19:831–836
  49. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853–861
  50. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In:  Dunaif A,  Givens JR,  Haseltine FP,  Merriam GR editor. Polycystic ovary syndrome. Boston: Blackwell Scientific; 1992;p. 377–384
  51. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25
  52. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:2694–2698
  53. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002;69(Suppl):2–15
  54. Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson PO. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod. 1998;13:2706–2711
  55. Ganie MA, Khurana ML, Eunice M, et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab. 2004;89:2756–2762
  56. Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf). 2000;52:587–594
  57. Moghetti P, Castello R, Negri C, et al. Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behavior. Fertil Steril. 1995;64:511–517
  58. Wysowski DK, Freiman JP, Tourtelot JB, Horton ML. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med. 1993;118:860–864
  59. Kelly CJ, Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol. 2002;147:217–221
  60. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000;85:139–146
  61. Romualdi D, Guido M, Ciampelli M, et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod. 2003;18:1210–1218
  62. Ibanez L, Ong K, Ferrer A, et al. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. J Clin Endocrinol Metab. 2003;88:2600–2606
  63. Ibanez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab. 2004;89:1592–1597
  64. Ibanez L, de Zegher F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. J Clin Endocrinol Metab. 2005;90:39–43
  65. Pasquali R, Antenucci D, Casmirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab. 1989;68:173–179
  66. Hermanns-Le T, Scheen A, Pierard GE. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. Am J Clin Dermatol. 2004;5:199–203
  67. Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50:541–553
  68. DeVillez RL, Jacobs JP, Szpunar CA, Warner ML. Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Arch Dermatol. 1994;130:303–307

☆ Supported in part by NIH Grants DA14041-03 (PAE) and K24HD40237 (JEN).

PII: S0738-081X(06)00046-0

doi: 10.1016/j.clindermatol.2006.04.004

Clinics in Dermatology
Volume 24, Issue 4 , Pages 289-298 , July 2006

Article Tools

* Image Usage & Resolution